RxDoctor Payments Data

Jarrod Jerry

Family · Greenbrier, ARNPI 1407143662

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 690 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,890in general payments, 2019–2025

Across 690 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$939
  • Pfizer$814
  • Amgen$784
  • GSK$651
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$10,890100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,890 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide122$137,581
MounjaroTirzepatide86$88,584
FarxigaDapagliflozin Propanediol91$75,120
EliquisApixaban58$52,821
JardianceEmpagliflozin79$47,330
Breztri AerosphereBudesonide/Glycopyr/Formoterol49$35,203
TrulicityDulaglutide33$31,978
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$28,934
LinzessLinaclotide32$24,341
Tresiba Flextouch U-200Insulin Degludec19$22,164
SynjardyEmpagliflozin/Metformin Hcl28$17,498
JanuviaSitagliptin Phosphate15$11,610
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$10,566
Synjardy XrEmpagliflozin/Metformin Hcl16$7,657
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$7,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,292$137,581122 claims
Lilly USA, LLCMounjaro, Trulicity$939$120,562119 claims
AstraZenecaFarxiga, Breztri Aerosphere$643$110,323140 claims
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr$268$72,486123 claims
PfizerEliquis$814$52,82158 claims
GSKTrelegy Ellipta, Breo Ellipta$651$35,60844 claims
AbbVieLinzess, Synthroid$1,674$25,57862 claims
MerckJanuvia$279$11,61015 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$326$6,03711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.

Other family in Greenbrier

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →